NovaBridge Biosciences (FRA:0VY)

Market Cap	321.96M +326.8%
Revenue (ttm)	n/a
Net Income	-22.44M
EPS	-0.26
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	2.740
Previous Close	2.720
Day's Range	2.740 - 2.740
52-Week Range	0.555 - 5.600
Beta	n/a
RSI	42.56
Earnings Date	Apr 1, 2026

About NovaBridge Biosciences

NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, imp...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 32
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0VY

Financial Performance

Financial numbers in USD